LOVE Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Cannara Biotech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.68 |
52 Week High | CA$1.04 |
52 Week Low | CA$0.52 |
Beta | 1.07 |
11 Month Change | 1.49% |
3 Month Change | 6.25% |
1 Year Change | -24.44% |
33 Year Change | -47.69% |
5 Year Change | -49.63% |
Change since IPO | -77.70% |
Recent News & Updates
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Recent updates
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Shareholder Returns
LOVE | CA Personal Products | CA Market | |
---|---|---|---|
7D | 11.5% | 1.1% | 2.2% |
1Y | -24.4% | 2.8% | 23.4% |
Return vs Industry: LOVE underperformed the Canadian Personal Products industry which returned 1.7% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
LOVE volatility | |
---|---|
LOVE Average Weekly Movement | 12.0% |
Personal Products Industry Average Movement | 9.6% |
Market Average Movement | 8.3% |
10% most volatile stocks in CA Market | 17.7% |
10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LOVE has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LOVE's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products. The company sells its products through wholesalers and online merchandisers.
Cannara Biotech Inc. Fundamentals Summary
LOVE fundamental statistics | |
---|---|
Market cap | CA$61.21m |
Earnings (TTM) | CA$5.32m |
Revenue (TTM) | CA$76.69m |
11.5x
P/E Ratio0.8x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LOVE income statement (TTM) | |
---|---|
Revenue | CA$76.69m |
Cost of Revenue | CA$47.81m |
Gross Profit | CA$28.88m |
Other Expenses | CA$23.56m |
Earnings | CA$5.32m |
Last Reported Earnings
May 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.059 |
Gross Margin | 37.65% |
Net Profit Margin | 6.93% |
Debt/Equity Ratio | 58.9% |
How did LOVE perform over the long term?
See historical performance and comparison